Highlights of This Issue 1049

REVIEWS

1051 Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation
Peter B. Bitterman and Vitaly A. Polunovsky

1062 Immunotherapy of Cancer with 4-1BB
Dass S. Vinay and Byoung S. Kwon

THERAPEUTIC DISCOVERY

1071 Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

1082 Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation
Junichi Matsu, Yoshihiro Tsuchi, Sakae Saito, Satomi Takahara, Junko Nakuda, Shigeo Sato, Hiromichi Kondo, Masaru Ushin, Masaaki Matsuura, Toshiki Watanabe, and Akihiro Tomida

1092 Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction
Marisa Meyers-Needham, Jocelyn A. Lewis, Salihencer, R. David Sentelle, Sahar A. Sudd, Christopher J. Clarke, Yusuf A. Hannun, Haakon Norell, Telma Martins da Palma, Michael Nishimura, Jacqueline M. Kraveka, Zohreh Khavandgar, Monzur Murshed, M. Ozgur Cevik, and Besim Ogretmen

PRECLINICAL DEVELOPMENT

1122 Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo
Girija Dasmahapatra, Dmitry Lembersky, Minkyong P. Son, Hiral Patel, Derek Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent, and Steven Grant

1143 ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors
Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, Jill M. Spoerke, Klaus P. Hoeffl, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Hui Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John Mofat, Marcia Belvin, and Mark R. Lackner

1155 Triggering Fbw7-Mediated Proteosomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis
Hui-Lin Huang, Heng-You Weng, Lu-Qin Wang, Chun-Hong Yu, Qiao-Kuan Huang, Pan-Pan Zhao, Jun-Zhi Wen, Hui Zhou, and Liang-Hu Qu
### miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial–Mesenchymal Transition Signaling

Peng Ru, Robert Steele, Philip Newhall, Nancy J. Phillips, Karoly Toth, and Ratna B. Ray

### Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas

Gangadhara R. Sareddy, Binoj C. Nair, Vijay K. Gonugunta, Quan-guang Zhang, Andrew Brenner, Darrell W. Brann, Rajeshwar Rao Tekmal, and Ratna K. Vadlamudi

### Multiple Antigenic Peptides Based on H-2Kb-Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo

Xu-Dong Tang, Guo-Zhen Wang, Jun Guo, Mu-Han Li, Chuan Li, Ning Li, Ya-Ling Chao, Chang-Zhu Li, Yu-Yun Wu, Chang-Jiang Hu, Dian-Chun Fang, and Shi-Ming Yang

### Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

Terence M. Williams, Athena R. Flecha, Paul Keller, Ashwin Ram, David Karnak, Stefanie Galbán, Craig J. Galbán, Brian D. Ross, Theodore S. Lawrence, Alnawaz Rehemtulla, and Judith Sebolt-Leopold

### Retraction

Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance

### Correction

Correction: Narciclasine, a Plant Growth Modulator, Activates Rho and Stress Fibers in Glioblastoma Cells

### ABOUT THE COVER

Several allosteric MEK inhibitors are in clinical development and have been designed to treat patients with tumors harboring RAS/RAF pathway alterations. Acquired resistance to this class of inhibitors is a pressing clinical problem. To identify strategies to overcome this resistance, Hatzivassiliou and colleagues derived and characterized three independent MEK inhibitor-resistant cell lines. All of the resistant cell lines harbored mutations in the allosteric binding pocket of MEK that is targeted by arylamine MEK inhibitors. In all cases the MEK resistant cell lines retained their addiction to the MAPK pathway and remained sensitive to a selective inhibitor of the ERK1/2 kinases, suggesting a role for ERK inhibitors in combating or preventing MEK inhibitor resistance. For details, see article by Hatzivassiliou and colleagues on page 1143.
Molecular Cancer Therapeutics

11 (5)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/5

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.